|
[1]
|
Barbieri, C.E., Baca, S.C., Lawrence, M.L., et al. (2012) Exome Sequencing Identifies Recurrent SPOP, FOXA1 and MED12 Mutations in Prostate Cancer. Nature Genetics, 44, 685-689.
http://dx.doi.org/10.1038/ng.2279
|
|
[2]
|
Kwon, J.E., La, M., Oh, K.H., et al. (2006) BTB Domain-Containing Speckle-Type POZ Protein (SPOP) Serves as an Adaptor of Daxx for Ubiquitination by Cul3-Based Ubiquitin Ligase. The Journal of Biological Chemistry, 281, 12664-12672.
http://dx.doi.org/10.1074/jbc.M600204200
|
|
[3]
|
Geng, C., He, B., Xu, L., Barbieri, C.E., Eedunuri, V.K., et al. (2013) Prostate Cancer-Associated Mutations in Speckle-Type POZ Protein (SPOP) Regulate Steroid Receptor Coactivator 3 Protein Turnover. Proceedings of the National Academy of Sciences of the USA, 110, 6997-7002.
http://dx.doi.org/10.1073/pnas.1304502110
|
|
[4]
|
Li, C., Ao, J., Fu, J., et al. (2011) Tumor-Suppressor Role for the SPOP Ubiquitin Ligase in Signal-Dependent Proteolysis of the Oncogenic Co-Activator SRC-3/AIB1. Oncogene, 30, 4350-4364.
http://dx.doi.org/10.1038/onc.2011.151
|
|
[5]
|
Zhang, Q., Zhang, L., Wang, B., et al. (2006) A Hedgehog-Induced BTB Protein Modulates Hedgehog Signaling by Degrading Ci/Gli Transcription Factor. Developmental Cell, 10, 719-729.
http://dx.doi.org/10.1016/j.devcel.2006.05.004
|
|
[6]
|
Theurillat, J.P., Udeshi, N.D., Errington, W.J., Svinkina, T., Baca, S.C., et al. (2014) Prostate Cancer. Ubiquitylome Analysis Identifies Dysregulation of Effector Substrates in SPOP-Mutant Prostate Cancer. Science, 346, 85-89.
http://dx.doi.org/10.1126/science.1250255
|
|
[7]
|
Xu, J., Wu, R.C. and O’Malley, B.W. (2009) Normal and Cancer-Related Functions of the p160 Steroid Receptor Co-Activator (SRC) Family. Nature Reviews Cancer, 9, 615-630.
http://dx.doi.org/10.1038/nrc2695
|
|
[8]
|
Gnanapragasam, V.J., Leung, H.Y., Pulimood, A.S., Neal, D.E. and Robson, C.N. (2001) Expression of RAC 3, a Steroid Hormone Receptor Co-Activator in Prostate Cancer. British Journal of Cancer, 85, 1928-1936.
http://dx.doi.org/10.1054/bjoc.2001.2179
|
|
[9]
|
Zhou, H.J., Yan, J., Luo, W., Ayala, G., Lin, S.H., Erdem, H., Ittmann, M., Tsai, S.Y. and Tsai, M.J. (2005) SRC-3 Is Required for Prostate Cancer Cell Proliferation and Survival. Cancer Research, 65, 7976-7983.
|
|
[10]
|
Kohler, J., Erlenkamp, G., Eberlin, A., Rumpf, T., Slynko, I., Metzger, E., Schüle, R., Sippl, W. and Jung, M. (2012) Lestaurtinib Inhibits Histone Phosphorylation and Androgen-Dependent Gene Expression in Prostate Cancer Cells. PLoS One, 7, e34973.
http://dx.doi.org/10.1371/journal.pone.0034973
|
|
[11]
|
Metzger, E., Müller, J.M., Ferrari, S., Buettner, R. and Schüle, R. (2003) A Novel Inducible Transactivation Domain in the Androgen Receptor: Implications for PRK in Prostate Cancer. The EMBO Journal, 22, 270-280.
http://dx.doi.org/10.1093/emboj/cdg023
|
|
[12]
|
Weeraratna, A.T., Dalrymple, S.L., Lamb, J.C., Denmeade, S.R., Miknyoczki, S., Dionne, C.A. and Isaacs, J.T. (2001) Pan-Trk Inhibition Decreases Metastasis and Enhances Host Survival in Experimental Models as a Result of Its Selective Induction of Apoptosis of Prostate Cancer Cells. Clinical Cancer Research, 7, 2237-2245.
|
|
[13]
|
Levis, M., Ravandi, F., Wang, E.S., Baer, M.R., Perl, A., Coutre, S., Erba, H., Stuart, R.K., et al. (2011) Results from a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for Patients with FLT3 Mutant AML in First Relapse. Blood, 117, 3294-3301.
http://dx.doi.org/10.1182/blood-2010-08-301796
|
|
[14]
|
Zhang, Q., Shi, Q., Chen, Y., Yue, T., Li, S., Wang, B. and Jiang, J. (2009) Multiple Ser/Thr-Rich Degrons Mediate the Degradation of Ci/Gli by the Cul3-HIB/SPOP E3 Ubiquitin Ligase. Proceedings of the National Academy of Sciences of the United States of America, 106, 21191-21196.
http://dx.doi.org/10.1073/pnas.0912008106
|
|
[15]
|
Chang, E.J., Ha, J., Kang, S.S., Lee, Z.H. and Kim, H.-H. (2011) AWP1 Binds to Tumor Necrosis Factor Receptor-Associated Factor 2 (TRAF2) and Is Involved in TRAF2-Mediated Nuclear Factor-κB Signaling. The International Journal of Biochemistry & Cell Biology, 43, 1612-1620.
http://dx.doi.org/10.1016/j.biocel.2011.07.010
|
|
[16]
|
Duan, W., Sun, B., Li, T.W., Tan, B.J., Lee, M.K. and Teo, T.S. (2000) Cloning and Characterization of AWP1, a Novel Protein That Associates with Serine/Threonine Kinase PRK-1 in Vivo. Gene, 256, 113-121.
http://dx.doi.org/10.1016/S0378-1119(00)00365-6
|
|
[17]
|
Collins, C., Carducci, M.A., Eisenberger, M.A., Isaacs, J.T., Partin, A.W., Pili, R., Sinibaldi, V.J., Walczak, J.S. and Denmeade, S.R. (2007) Preclinical and Clinical Studies with the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint. Cancer Biology & Therapy, 6, 1360-1367.
http://dx.doi.org/10.4161/cbt.6.9.4541
|
|
[18]
|
Yi, P., Feng, Q., Amazit, L., Lonard, D.M., Tsai, S.Y., Tsai, M.J. and O’Malley, B.W. (2008) Atypical Protein Kinase C Regulates Dual Pathways for Degradation of the Oncogenic Coactivator SRC-3/AIB1. Molecular Cell, 29, 465-476.
http://dx.doi.org/10.1016/j.molcel.2007.12.030
|
|
[19]
|
Festuccia, C., Muzi, P., Gravina, G.L., Millimaggi, D., Speca, S., Dolo, V., Ricevuto, E., Vicentini, C. and Bologna, M. (2007) Tyrosine Kinase Inhibitor CEP-701 Blocks the NTRK1/NGF Receptor and Limits the Invasive Capability of Prostate Cancer Cells in Vitro. International Journal of Oncology, 30, 193-200.
http://dx.doi.org/10.3892/ijo.30.1.193
|
|
[20]
|
George, D.J., Dionne, C.A., Jani, J., Angeles, T., Murakata, C., Lamb, J. and Isaacs, J.T. (1999) Sustained in Vivo Regression of Dunning H Rat Prostate Cancers Treated with Combinations of Androgen Ablation and Trk Tyrosine Kinase Inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Research, 59, 2395-2401.
|